HDAC Inhibitor AR-42 Suppresses Muscle Wasting in Cancer Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in preventing or halting the progression of cancer-related cachexia, a condition characterized by muscle wasting and weight loss in cancer patients, with no FDA-approved treatments available to manage muscle wasting in cachectic patients.
Innovation Solution
Administration of the HDAC class 1 and 2b inhibitor AR-42 to cancer patients to suppress cachexia, maintaining weight and reducing muscle wasting, independent of tumor load reduction, by downregulating pro-cachexia mediators and reprogramming cell metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If HDAC inhibitors (e.g., Trichostatin A) are administered to suppress cachexia, then protein degradation may be reduced, but hyperacetylation can increase protein degradation leading to increased muscle wasting and cachexia
Solution Approach 1:
The patent changes the chemical structure parameters of HDAC inhibitors by introducing specific substituents (halogen atoms at positions 2 and 4, methoxy group at position 3) on the benzamide core structure. This structural modification alters the biological activity parameters, producing inhibitors with improved selectivity and reduced side effects compared to conventional HDAC inhibitors like Trichostatin A.
Solution Approach 2:
The patent applies local quality modification by placing specific functional groups (halogen atoms and methoxy group) at specific positions on the benzamide molecule. This localized structural modification creates differential effects on HDAC isoforms, achieving selective inhibition that reduces harmful hyperacetylation while maintaining beneficial anti-cachexia effects.
2Weight of moving object
If conventional nutritional support is provided to cachectic patients, then weight loss may be slowed, but it does not reverse skeletal muscle mass depletion
Solution Approach 1:
The patent introduces HDAC inhibitors as an intermediary substance that mediates between nutritional support and muscle mass preservation. The inhibitors act on the molecular level to modulate protein degradation pathways, working synergistically with nutritional support to achieve both weight maintenance and muscle mass preservation, whereas nutritional support alone only addresses weight but not muscle quality.
3Loss of substance
If HDAC inhibitors are used to treat cachexia, then muscle wasting may be reduced, but contradictory and conflicting results have been observed in different studies
Solution Approach 1:
The patent modifies key parameters of HDAC inhibitors including molecular weight, lipophilicity, and enzymatic inhibition constants through strategic placement of halogen and methoxy substituents. These parameter changes produce compounds with optimized pharmacokinetic and pharmacodynamic properties, leading to more consistent and reliable therapeutic effects across different study conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AR-42 effectively maintains skeletal muscle weight, reduces cachexia-induced adipose tissue loss, and prolongs survival in animal models of cancer cachexia, demonstrating its ability to suppress muscle wasting and improve survival rates without affecting tumor growth.
Implementation Method 1
Administration of the HDAC class 1 and 2b inhibitor AR-42 to suppress cachexia
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.